IFNA1 and allergic asthma: In a recent NIAID-sponsored trial of omalizumab in children with allergic asthma, RV-induced pDC IFN responses were significantly increased in the group who received this IgE-reducing treatment, and this improved antiviral response was associated with lower exacerbations (31, 32).